Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C113655
http://purl.obolibrary.org/obo/NCIT_C113655
|
|---|---|
| Preferred Name | Lorlatinib |
| Definitions |
An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells. |
|---|---|
| label | Lorlatinib
|
| prefLabel | Lorlatinib
|
| in_subset |
See more
See less
|
| Preferred_Name | Lorlatinib
|
| Is_Value_For_GDC_Property | |
| Display_Name | Lorlatinib
|
| Maps_To | Lorlatinib
|
| PDQ_Open_Trial_Search_ID | 756930
|
| Has_Target | |
| UMLS_CUI | C3884739
|
| FDA_UNII_Code | OSP71S83EU
|
| prefixIRI | NCIT:C113655
|
| Accepted_Therapeutic_Use_For | anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
|
| NCI_Drug_Dictionary_ID | 756930
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C113655
|
| type | |
| PDQ_Closed_Trial_Search_ID | 756930
|
| Semantic_Type | Pharmacologic Substance
|
| CAS_Registry | 1454846-35-5
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |